Patents
Our laboratory is committed to translating innovative research into practical solutions with real-world impact. This commitment is reflected in a growing portfolio of U.S. patents spanning gene therapy, antiviral technologies, biosensing platforms for virus and antibody detection, and advanced antimicrobial materials. These inventions demonstrate our focus on advancing biotechnology, infectious disease research, and biomedical innovation to address global health challenges. The following patents have been issued by the United States Patent and Trademark Office (USPTO):
- US Patent: Recombinant retroviral vectors for gene therapy (USPTO already issued a notice of allowance, and the patent number will be issued in July 2026)
- US Patent 11,071,337: Personal protection device against viruses and article of apparel and device and method for making a vaccine.
- US Patent 11,493,514: Method and system for virus and protein-antibody interactions detection and monitoring based on optical light intensity and electrical parameters.
- US Patent 11,866,545: Anti-microbial bi-metallic polymeric composite.